[1] |
Robert T, Berthelot L, Cambier A,et al.Molecular insights into the pathogenesis of IgA nephropathy[J].Trends Mol Med,2015,21(12):762-775.
|
[2] |
Mestecky J, Raska M, Julian BA, et al.IgA nephropathy:molecular mechanisms of the disease[J].Annu Rev Pathol, 2013, 8(1): 217-240.
|
[3] |
Pabst O.New concepts in the generation and functions of IgA[J].Nat Rev Immunol,2012,12(12):821-832.
|
[4] |
Zhao N, Hou P, Lv J,et al.The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression[J].Kidney Int,2012,82(7):790-796.
|
[5] |
Placzek WJ, Yanagawa H, Makita Y, et al. Serum galactose-deficient-IgA1 and IgG autoantibodies correlate in patients with IgA nephropathy[J]. PLoS One, 2018, 13(1): e0190967.
|
[6] |
Zhang C, Zeng X, Li Z,et al. Immunoglobulin A nephropathy:current progress and future directions[J]. Transl Res,2015,166(2):134-144.
|
[7] |
Suzuki H, Yasutake J, Makita Y, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis[J]. Kidney Int, 2018, 93(3): 700-705.
|
[8] |
Suzuki H, Raska M, Yamada K,et al.Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-Ⅱ enzymes[J].J Biol Chem, 2014, 289(8): 5330-5339.
|
[9] |
Malycha F, Eggermann T, Hristov M.No evidence for a role of cosmc-chaperone mutations in European IgA nephropathy patients[J].Nephrol Dial Transplant, 2009, 24(1): 321-324.
|
[10] |
Sun Q, Zhang J, Zhou N,et al. DNA methylation in Cosmc promoter region and aberrantly glycosylated IgA1 associated with pediatric IgA nephropathy[J]. PLoS One,2015,10(2):e0112305.
|
[11] |
Takahashi K, Raska M, Stuchlova Horynova M, et al. Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy [J]. PLoS One, 2014, 9(6): e99026.
|
[12] |
Steirer LM, Park EI, Townsend RR, et al.The asialoglycoprotein receptor regulates levels of plasma glycoproteins terminating with sialic acid a2 , 6-galactose[J].J Biol Chem, 2009, 284(6): 3777-3783.
|
[13] |
Al-Lawati Ali I, Reich Heather N. Is there a role for immunosuppression in immunoglobulin A nephropathy?[J].Nephrol Dial Transplant, 2017, 32(Suppl 1): i30-i36.
|
[14] |
Wyatt RJ, Julian BA. IgA nephropathy[J]. N Engl J Med,2013,368(25):2402-2414.
|
[15] |
Potter CS, Wang Z, Silva KA,et al. Chronic proliferative dermatitis in Sharpin null mice : development of an autoinflammatory disease in the absence of B and T lymphocytes and IL4/IL13 signaling[J].PLoS One,2014,9(1):e85666.
|
[16] |
Liu Y, Liu H, Peng Y, et al. New insights into the pathogenesis of IgA nephropathy: do toll like receptor 9-B cell activation factor-IgA class switching recombination signaling axis induce IgA hyper-production?[J]. Ren Fail, 2014, 36(6): 970-973.
|
[17] |
Nakata J, Suzuki Y, Suzuki H, et al. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy[J]. PLoS One, 2014, 9(2): e89707.
|
[18] |
Xie LS, Qin W, Fan JM, et al. The role of C1GALT1C1 in lipopolysaccharide-induced IgA1 aberrant O-glycosylation in IgA nephropathy [J] . Clin Invest Med, 2010, 33(1): 5-13.
|
[19] |
Emancipator SN.Prospects and perspectives on IgA nephropathy from animal models[J].Contrib Nephrol,2011,169:126-152.
|
[20] |
Kiryluk K, Novak J.The genetics and immunobiology of IgA nephropathy[J].J Clin Invest, 2014, 124(6): 2325-2332.
|
[21] |
Ji L, Chen X, Zhong X, et al. Astragalus membranaceus up-regulate Cosmc expression and reverse IgA dys-glycosylation in IgA nephropathy.[J]BMC Complement Altern Med, 2014, 14: 195.
|
[22] |
高植明.黄芪提取物对IgAN患者IgA1异常糖基化的作用及其分子机制研究[J].北方药学,2016, 13(8): 115-116.
|
[23] |
沈世忠,杨忠民,蔡佳盈等.黄芪注射液对IgA肾病患者免疫球蛋白分子异常糖基化及Cosmc基因表达的影响[J].中国老年学杂志,2017, 37(11): 2788-2789.
|
[24] |
Chen F, Ma YL, Ding H, et al. Effects of tripterygium wilfordii glycosides on regulatory T cells and Th17 in an IgA nephropathy rat model[J]. Genet Mol Res, 2015,14(4):14900-14907.
|
[25] |
申鹏霄,赵根尚,吴双,等.雷公藤多甙片对IgA肾病大鼠炎性因子及肾功能的影响[J].中华实验外科杂志,2017, 34(4): 631-634.
|
[26] |
朱彩凤,朱斌,包自阳,等.雷公藤内酯醇对IgA肾病大鼠蛋白尿和nephrin、podocin蛋白及mRNA表达的影响[J].中国中西医结合肾病杂志,2015, (2): 106-109.
|
[27] |
Li P, Chen YZ, Lin HL, et al. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial[J]. Trials, 2017, 18(1): 170.
|
[28] |
卢嫣,韩世盛,王怡. 粘膜方对IgA肾病患者外周血B淋巴细胞Comsc表达的影响[J].中国中西医结合肾病杂志,2016, 17(10): 874-876.
|
[29] |
周丽霞,熊佩华,费梅,等.活血养阴方对IgA肾病大鼠的治疗作用[J].中国中西医结合肾病杂志,2015, (8): 674-676.
|
[30] |
彭亚军,李旭华,何泽云,等.六味地黄汤对IgA肾病大鼠外周血C1 GALT1及Cosmc mRNA表达影响研究[J].中国中西医结合肾病杂志,2016, 17(3): 211-214.
|
[31] |
Hastings MC, Moldoveanu Z, Suzuki H,et al.Biomarkers in IgA nephropathy relationship to pathogenetic hits[J].Expert Opin Med Diagn,2013,7(6):615-627.
|
[32] |
Kiryluk K, Moldoveanu Z, Sanders JT,et al.Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch-Schönlein purpura nephritis[J].Kidney Int,2011,80(1):79-87.
|